- US-listed companies
- Akebia Therapeutics, Inc.
- Income statement
Akebia Therapeutics, Inc.AKBA
Market cap
$422.84M
P/E ratio
| 2014/12 | 2015/12 | 2016/12 | 2017/12 | 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | |
| Revenue | - | - | - | - | 208 | 335 | 295 | 214 | 293 | 195 | 160 |
| Revenue growth (%) | - | - | - | - | - | ||||||
| Cost of revenue | - | - | - | - | 8 | 145 | 296 | 153 | 85 | 74 | 63 |
| Research & development | 25 | 43 | 116 | 231 | 291 | 323 | 218 | 148 | 129 | 63 | 38 |
| Selling, general & administrative | - | - | - | - | 87 | 149 | 154 | 174 | 139 | 100 | 107 |
| Operating margin (%) | - | - | - | - | |||||||
| Operating income | -38 | -62 | -136 | -80 | -178 | -286 | -376 | -265 | -79 | -46 | -50 |
| Operating expenses | 38 | 62 | 138 | 258 | 378 | 476 | 376 | 326 | 287 | 167 | 147 |
| Income before tax | - | - | - | - | -172 | -286 | -383 | -283 | -93 | -52 | -69 |
| Pretax margin (%) | - | - | - | - | -82.8 | -85.5 | -129.9 | -132.4 | -31.6 | -26.7 | -43.3 |
| Provision for income taxes | - | - | - | - | -28 | -7 | - | - | - | - | - |
| Effective tax rate (%) | - | - | - | - | - | - | - | - | - | ||
| Net income | -37,034,039 | -61 | -136 | -77 | -144 | -280 | -383 | -283 | -93 | -52 | -69 |
| Net income margin (%) | - | - | - | - | |||||||
| Earnings per share | - | - | - | - | - | - | - | -1.7 | -0.51 | -0.28 | -0.33 |
| Diluted EPS | - | - | - | - | - | - | - | -1.7 | -0.51 | -0.28 | -0.33 |
| EBITDA | - | - | - | - | |||||||
| EBITDA margin (%) | - | - | - | - | - | - |